within Pharmacolibrary.Drugs.ATC.G;

model G03FA13
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.0008333333333333334,
    adminDuration  = 600,
    adminMass      = 0.25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.0024,
    k12             = 15,
    k21             = 15
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03FA13</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Norgestimate and estrogen is a combined oral contraceptive containing norgestimate, a progestin, and an estrogen, usually ethinyl estradiol. It is used for the prevention of pregnancy and may also be prescribed to manage menstrual disorders and acne. This drug is approved and commonly used worldwide as a contraceptive in women of reproductive age.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for norgestimate and ethinyl estradiol in healthy adult women, based on published studies of oral contraceptive use.</p><h4>References</h4><ol><li><p>Bhardwaj, R, et al., &amp; Bertz, RJ (2023). Effects of rimegepant 75 mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants. <i>Headache</i> 63(5) 652–662. DOI:<a href=&quot;https://doi.org/10.1111/head.14512&quot;>10.1111/head.14512</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37140071/&quot;>https://pubmed.ncbi.nlm.nih.gov/37140071</a></p></li><li><p>Song, IH, et al., &amp; Piscitelli, SC (2015). Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol. <i>The Annals of pharmacotherapy</i> 49(7) 784–789. DOI:<a href=&quot;https://doi.org/10.1177/1060028015580637&quot;>10.1177/1060028015580637</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25862012/&quot;>https://pubmed.ncbi.nlm.nih.gov/25862012</a></p></li><li><p>Bifano, M, et al., &amp; Bertz, R (2014). Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate. <i>Antiviral therapy</i> 19(5) 511–519. DOI:<a href=&quot;https://doi.org/10.3851/IMP2718&quot;>10.3851/IMP2718</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24343001/&quot;>https://pubmed.ncbi.nlm.nih.gov/24343001</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03FA13;
